drugset
drugset / Trial / NCT06738836

A Study to Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C]-EDG-7500

NCT06738836 ↗

Phase 1 Completed 8 enrolled Edgewise Therapeutics, Inc.
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to: 1. Assess the mass balance (i.e., the cumulative elimination of 14C-related material in urine and feces, compared to the administered amount of radioactive isotope) of \[14C\]-EDG-7500 following a single oral dose of EDG-7500 containing a radioactive tracer, in healthy, adult male subjects. 2. Characterize the pharmacokinetics of EDG-7500 in plasma and of 14C-related material in whole blood, plasma, urine and feces following a single oral dose of EDG-7500 containing a radioactive tracer, in healthy, adult male subjects.

Timeline

Start
2024-12-03
Primary completion
2025-01-17
Completion
2025-01-17

Drugs

EvaluationDrugModalityDoseRoute
Subject EDG-7500 Unknown — Oral

Indications

No indication recorded.